These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 27222478)

  • 1. Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice.
    Maschalidi S; Sepulveda FE; Garrigue A; Fischer A; de Saint Basile G
    Blood; 2016 Jul; 128(1):60-71. PubMed ID: 27222478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effects of itacitinib, fedratinib, and ruxolitinib in mouse models of hemophagocytic lymphohistiocytosis.
    Keenan C; Albeituni S; Oak N; Stroh A; Tillman HS; Wang Y; Freeman BB; Alemán-Arteaga S; Meyer LK; Woods R; Verbist KC; Zhou Y; Cheng C; Nichols KE
    Blood; 2024 Jun; 143(23):2386-2400. PubMed ID: 38446698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis.
    Das R; Guan P; Sprague L; Verbist K; Tedrick P; An QA; Cheng C; Kurachi M; Levine R; Wherry EJ; Canna SW; Behrens EM; Nichols KE
    Blood; 2016 Mar; 127(13):1666-75. PubMed ID: 26825707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ruxolitinib-loaded cytokine nanosponge alleviated the cytokine storm and dampened macrophage overactivation for the treatment of hemophagocytic lymphohistiocytosis.
    Wang H; Wang Y; Liu H; Li X; Sun C; Pang Z; Zhang B; Hu Y
    Int J Pharm; 2024 May; 657():124127. PubMed ID: 38621611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ruxolitinib for secondary hemophagocytic lymphohistiocytosis: First case report.
    Sin JH; Zangardi ML
    Hematol Oncol Stem Cell Ther; 2019 Sep; 12(3):166-170. PubMed ID: 28834694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JAK/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation.
    Meyer LK; Verbist KC; Albeituni S; Scull BP; Bassett RC; Stroh AN; Tillman H; Allen CE; Hermiston ML; Nichols KE
    Blood; 2020 Aug; 136(6):657-668. PubMed ID: 32530039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JAK inhibition for murine HLH requires complete blockade of IFN-γ signaling and is limited by toxicity of JAK2 inhibition.
    Chaturvedi V; Lakes N; Tran M; Castillo N; Jordan MB
    Blood; 2021 Sep; 138(12):1034-1039. PubMed ID: 34232994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis.
    Albeituni S; Verbist KC; Tedrick PE; Tillman H; Picarsic J; Bassett R; Nichols KE
    Blood; 2019 Jul; 134(2):147-159. PubMed ID: 31015190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis.
    Keenan C; Nichols KE; Albeituni S
    Front Immunol; 2021; 12():614704. PubMed ID: 33664745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Griscelli syndrome type 2 murine model of hemophagocytic lymphohistiocytosis (HLH).
    Pachlopnik Schmid J; Ho CH; Diana J; Pivert G; Lehuen A; Geissmann F; Fischer A; de Saint Basile G
    Eur J Immunol; 2008 Nov; 38(11):3219-25. PubMed ID: 18991284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular and transcriptional impacts of Janus kinase and/or IFN-gamma inhibition in a mouse model of primary hemophagocytic lymphohistiocytosis.
    Albeituni S; Oak N; Tillman HS; Stroh A; Keenan C; Bloom M; Nichols KE
    Front Immunol; 2023; 14():1137037. PubMed ID: 37228616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IFN-γ and CD25 drive distinct pathologic features during hemophagocytic lymphohistiocytosis.
    Humblet-Baron S; Franckaert D; Dooley J; Ailal F; Bousfiha A; Deswarte C; Oleaga-Quintas C; Casanova JL; Bustamante J; Liston A
    J Allergy Clin Immunol; 2019 Jun; 143(6):2215-2226.e7. PubMed ID: 30578871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct severity of HLH in both human and murine mutants with complete loss of cytotoxic effector PRF1, RAB27A, and STX11.
    Sepulveda FE; Debeurme F; Ménasché G; Kurowska M; Côte M; Pachlopnik Schmid J; Fischer A; de Saint Basile G
    Blood; 2013 Jan; 121(4):595-603. PubMed ID: 23160464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alleviating the storm: ruxolitinib in HLH.
    La Rosée P
    Blood; 2016 Mar; 127(13):1626-7. PubMed ID: 27034417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralization of IFNgamma defeats haemophagocytosis in LCMV-infected perforin- and Rab27a-deficient mice.
    Pachlopnik Schmid J; Ho CH; Chrétien F; Lefebvre JM; Pivert G; Kosco-Vilbois M; Ferlin W; Geissmann F; Fischer A; de Saint Basile G
    EMBO Mol Med; 2009 May; 1(2):112-24. PubMed ID: 20049711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polygenic mutations in the cytotoxicity pathway increase susceptibility to develop HLH immunopathology in mice.
    Sepulveda FE; Garrigue A; Maschalidi S; Garfa-Traore M; Ménasché G; Fischer A; de Saint Basile G
    Blood; 2016 Apr; 127(17):2113-21. PubMed ID: 26864340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: A case series.
    Hansen S; Alduaij W; Biggs CM; Belga S; Luecke K; Merkeley H; Chen LYC
    Eur J Haematol; 2021 May; 106(5):654-661. PubMed ID: 33523540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mouse Cytomegalovirus Infection in BALB/c Mice Resembles Virus-Associated Secondary Hemophagocytic Lymphohistiocytosis and Shows a Pathogenesis Distinct from Primary Hemophagocytic Lymphohistiocytosis.
    Brisse E; Imbrechts M; Put K; Avau A; Mitera T; Berghmans N; Rutgeerts O; Waer M; Ninivaggi M; Kelchtermans H; Boon L; Snoeck R; Wouters CH; Andrei G; Matthys P
    J Immunol; 2016 Apr; 196(7):3124-34. PubMed ID: 26903481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined IFN-γ and JAK inhibition to treat hemophagocytic lymphohistiocytosis in mice.
    Joly JA; Vallée A; Bourdin B; Bourbonnais S; Patey N; Gaboury L; Théorêt Y; Decaluwe H
    J Allergy Clin Immunol; 2023 Jan; 151(1):247-259.e7. PubMed ID: 35973477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repression of interferon β-regulated cytokines by the JAK1/2 inhibitor ruxolitinib in inflammatory human macrophages.
    Febvre-James M; Lecureur V; Augagneur Y; Mayati A; Fardel O
    Int Immunopharmacol; 2018 Jan; 54():354-365. PubMed ID: 29202299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.